Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.7 USD | -1.85% | +0.47% | -44.92% |
08/05 | Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating | MT |
08/05 | Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.92% | 674M | |
+33.24% | 709B | |
+30.77% | 595B | |
-1.98% | 367B | |
+20.29% | 334B | |
+5.18% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.47% | 171B |
- Stock Market
- Equities
- EYPT Stock
- News EyePoint Pharmaceuticals, Inc.
- Eyepoint Pharmaceuticals Insider Sold Shares Worth $795,191, According to a Recent SEC Filing